Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF, page-358

First 358 Last

Share
Profile

Follow
Davisite

19,963 Posts.

7322

12/01/21

13:07

Post #: 50110324
Share

Originally posted by bedger ↑

Old report:

"Despite significant reduction in the pre-specified endpoint of cardiac death, there was no reduction in recurrent non-fatal decompensated heart failure events, which was the trial’s primary endpoint".

New report:

"Patients who received rexlemestrocel-L had a 68% reduction in the rate of recurrent hospitalizations from non-fatal heart attacks or strokes compared with controls, with a hospitalization rate of 1.90 per 100 patient years of follow-up in the rexlemestrocel-L arm versus 5.95 per 100 patient-years of follow-up in the control arm (p=0.0002)".

Happy to be corrected but decompensated heart events can include things like difficulty breathing and other aspects of extreme discomfort. Jeez, looking at these results MSB really did mess up on the primary endpoint. Such a shame they did not pick a more cardiac specific primary endpoint.

These results are different and bode very well for a collaboration and better for FDA in my modest opinion and knowledge of cardiac medicine.

Expand

100% caused by management failure. When I read results like this and see what could have been with different management I want to weep.

The pathway forward is going to be a new Phase III trial. The FDA will not approve a new treatment that failed its primary objective, no matter how positive the secondary endpoint data. A complete and utter clusterf...

MSB Price at posting: $2.62 Sentiment: Sell Disclosure: Not Held
4 Upvote

0 Great analysis

Reply

Top Stories

ASX Market Close: Iron awe keeps the XJO tracking along

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

TLX

Telix sinks as US regulator SEC issues subpoena over claims

Japan tariff deal inked at 15% – as long as US gets half a trillion of investment

TMG

Trigg brings famed Finnish metals refiner – and its tech – onboard to bolster antimony processing

First 358 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $2.39		Change 0.110(4.82%)		Mkt cap ! $3.059B

Open	High	Low	Value	Volume
$2.31	$2.43	$2.30	$15.10M	6.360M

Buyers (Bids)

No.	Vol.	Price($)
3	9186	$2.38

Sellers (Offers)

Price($)	Vol.	No.
$2.40	22000	3

View Market Depth

No.	Vol.	Price($)
2	8586	2.380
4	50208	2.370
4	39275	2.360
4	30375	2.350
2	953	2.340

Price($)	Vol.	No.
2.400	22000	3
2.410	17500	4
2.420	22621	6
2.430	48680	6
2.440	6900	2

Last trade - 16.11pm 23/07/2025 (20 minute delay)

MSB (ASX) Chart

Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF, page-358

ASX Market Close: Iron awe keeps the XJO tracking along

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

Telix sinks as US regulator SEC issues subpoena over claims

Japan tariff deal inked at 15% – as long as US gets half a trillion of investment

Trigg brings famed Finnish metals refiner – and its tech – onboard to bolster antimony processing

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF, page-358

Top Stories

ASX Market Close: Iron awe keeps the XJO tracking along

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

Telix sinks as US regulator SEC issues subpoena over claims

Japan tariff deal inked at 15% – as long as US gets half a trillion of investment

Trigg brings famed Finnish metals refiner – and its tech – onboard to bolster antimony processing

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News